comparemela.com
Home
Live Updates
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phas
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phas
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related Keywords
China ,
Beijing ,
Peking ,
South Korea ,
Massachusetts ,
United States ,
Han ,
James Xue ,
Chris Brinzey ,
China Alliance For Rare Disease ,
University Of Washington School Medicine ,
Canbridge Pharmaceuticals Inc ,
Union Medical College Hospital ,
Planet Communications ,
Umass Chan Medical School ,
National Collaborative Network For The Diagnosis ,
Bing Han ,
Chief Physician ,
Peking Union Medical College Hospital ,
Wuxi Biologics ,
China Alliance ,
Rare Disease ,
National Collaborative Network ,
Rare Diseases ,
Chan Medical School ,
Washington School ,
Scriptr Global ,
Pharmaceuticals Inc ,
Investor Relations ,
Business Wire ,
Technology ,
Health ,
Business ,